Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XL10
|
| gptkbp:brand |
gptkb:Carvykti
|
| gptkbp:developedBy |
gptkb:Legend_Biotech
gptkb:Janssen_Pharmaceuticals |
| https://www.w3.org/2000/01/rdf-schema#label |
Ciltacabtagene autoleucel
|
| gptkbp:indication |
relapsed or refractory multiple myeloma
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:mechanismOfAction |
genetically modified autologous T cells
targets B-cell maturation antigen |
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
infections
neurotoxicity cytokine release syndrome hematologic toxicities |
| gptkbp:source |
autologous T cells
|
| gptkbp:target |
gptkb:BCMA
|
| gptkbp:treatment |
personalized medicine
|
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:bfsParent |
gptkb:CAR-T_cell_therapies
|
| gptkbp:bfsLayer |
6
|